



**2019
ANNUAL REPORT SECTION 1115
State of Indiana**

END STAGE RENAL DISEASE (ESRD) DEMONSTRATION
PROJECT NUMBER: 11-W-00237/5
PROJECT NUMBER: 11-W-0030/5

REPORTING PERIOD:

Demonstration Year: 4 (1/01/19-12/31/19)
Federal Fiscal Quarter: 2/2019 (1/19/-3/19)
Federal Fiscal Quarter: 3/2019 (4/19-6/19)
Federal Fiscal Quarter: 4/2019 (7/19-9/19)
Federal Fiscal Quarter: 1/2020 (10/19-12/19)

DEMONSTRATION OFFICER:

Ms. Shanna Janu
Centers for Medicare & Medicaid Services
Center for Medicaid & CHIP Services
Mail Stop: S2-03-14
7500 Security Boulevard
Baltimore, MD 21244-1850
Telephone: 410-786-4252
Email: Shanna.janu@cms.hhs.gov

COMMUNICATIONS TO:

Shanna Janu and
Ms. Ruth Hughes
Associate Regional Administrator
Division of Medicaid and Children Health Operations
233 North Michigan Avenue, Suite 600
Chicago, IL 60601
Email: Ruth.hughes@cms.hhs.gov

Date Submitted to CMS: 05/07/2020

The State of Indiana respectfully submits the 2019 Annual End Stage Renal Disease (ESRD) 1115 Demonstration Report.

If there are any questions or comments regarding these changes please do not hesitate to contact the State contacts listed below.

State Contacts

Primary Contact	Secondary Contact
Sue Beecher Quality and Outcomes Director Office of Medicaid Policy and Planning Family and Social Services Administration W374 IGC-S MS07 402 W Washington St. Indianapolis, IN 46204-2739 Telephone: 317- 234-7887 susan.beecher@fssa.in.gov	Kelsey Pund Quality Analyst Office of Medicaid Policy and Planning Family and Social Services Administration W374 IGC-S, MS 07 402 W Washington St. Indianapolis, IN 46204-2739 Telephone: 317-234-0109 kelsey.pund@fssa.in.gov

INDIANA FAMILY AND SOCIAL SERVICES ADMINISTRATION

END STAGE RENAL DISEASE (ESRD) 2019 ANNUAL REPORT

1/1/19 - 12/31/19

CENTERS FOR MEDICARE & MEDICAID SERVICES

NUMBER: 11-W-00303/5

TITLE: End Stage Renal Disease

“According to the [U.S. Renal Data System Annual Data Report](#), chronic kidney failure, also called end-stage renal disease, or ESRD affects almost 650,000 people per year in the United States. Often progressing slowly over a period of years, kidney failure is measured in five stages - and ESRD is the final stage when kidneys no longer function on their own. The job of healthy kidneys is to filter waste and fluids from building up in the body. However, when kidneys fail, patients must undergo lifelong dialysis treatments to replace the kidney’s filtering function. The other choice for an ESRD patient, if eligible, is a kidney transplant, which requires a donor match, major surgery, and a lifetime of medications to prevent rejection”
(<https://www.medicare.gov/pubs/pdf/10128-medicare-coverage-esrd.pdf>).

ANNUAL REPORT

Goal of Report

The goal of this **END STAGE RENAL DISEASE (ESRD) ANNUAL REPORT** is to provide a progress report for the ESRD activities conducted from January 1, 2019 through December 31, 2019 required by the Centers for Medicare & Medicaid Services (CMS) and outlined in the ESRD Special Terms and Conditions (STC’s). This report focuses on operational, enrollment, and fiscal accomplishments and summarizes the four Quarterly Reports provided to CMS in this year. This Annual Report provides data changes and updates to the 2018 Enrollment numbers. In addition, prior ESRD enrollment trends are presented at the end of the document.

Executive Summary

Indiana’s Healthy Indiana Plan (HIP) 1.0 demonstration began in 1994 to supplement state plan benefits for Medicaid eligible children and otherwise eligible adults who are not aged, blind or disabled. HIP 1.0 was scheduled to expire at the end of 2013, but was extended for an additional year through December 31, 2014.

In May 2014, CMS approved an amendment to include former spend down enrollees diagnosed with End Stage Renal Disease (ESRD) as a HIP 1.0 demonstration population. ESRD enrollees are Medicare beneficiaries in need of supplemental health care coverage. By providing coverage through HIP, beneficiaries were able to access kidney transplant and related services that they might not be able to afford without the additional supplemental benefits.

In January 2015, CMS approved the Healthy Indiana Plan (HIP) 2.0 demonstration whereby former HIP 1.0 enrollees transitioned into the HIP 2.0 demonstration. The ESRD enrollees were

the only population remaining in the HIP 1.0 demonstration and the demonstration was operated on a temporary extension until its approval on July 28, 2016. It was renamed the End Stage Renal Disease (ESRD) Demonstration.

The ESRD Demonstration continues to provide coverage for individuals with ESRD that are not currently eligible under the Medicaid state plan. The demonstration originally covered approximately 1,216 enrollees with ESRD, who would otherwise be unable to access kidney transplant services. Corrections made with data processing showed there were 612 enrollees in Population 1 and 604 enrollees in Population 2. With this demonstration extension, Indiana expects to achieve program objectives.

The End Stage Renal Disease (ESRD) 1115 demonstration waiver provides Medicare-enrolled individuals with ESRD, who are otherwise ineligible for Medicaid, with wrap-around fee-for-service coverage including supplemental coverage for kidney transplant services. The participants in the demonstration receive services through a fee-for-service delivery system and will be subject to the same cost sharing as described in the approved Medicaid state plan.

The objectives of this approved demonstration are:

- Increase overall coverage of low-income individuals with a diagnosis of ESRD; and
- Ensure access to comprehensive coverage for low-income individuals with a diagnosis of ESRD and primary coverage through Medicare.

Program Statistics

Decreased Enrollment

As seen in Table 1 2019, ESRD enrollment decreased throughout the year for both Population 1 and Population 2 enrollees. Overall, DY 2019 enrollment is lower than DY 2018.

<i>Table 1 2019</i>				
ESRD-Enrollment				
Source: Family & Social Services Administration (FSSA) Data and Analytics				
Report the unduplicated count of members enrolled as of the last day of the reporting quarters.				
	Total by Quarter			
Population	3/19	6/19	9/19	12/19
Demonstration Population 1 – Former Spend Down Individuals/Number of Enrollees	42	41	40	39
Demonstration Population 2 - Number of New Enrollees	348	341	335	327
Demonstration Population Total Number of Enrollees	390	382	375	366

<i>Table 2 2018</i>				
ESRD-Enrollment				
Source: Family & Social Services Administration (FSSA) Data and Analytics				
Report the unduplicated count of members enrolled as of the last day of the reporting quarters.				
	Total by Quarter			
Population	3/18	6/18	9/18	12/18
Demonstration Population 1 – Former Spend Down Individuals/Number of Enrollees	42	42	42	42

Demonstration Population 2 - Number of New Enrollees	348	341	335	327
Demonstration Population Total Number of Enrollees	390	382	375	366

During the first quarter of FFY1019 staff from the Quality and Outcomes Section of the Indiana Office of Medicaid Policy and Planning (OMPP) became involved in the project to revise the 2018 CMS-64 to include data on the end stage renal disease population and budget neutrality for this waiver. In meetings with Enrollment staff it was discovered that the Demonstration Population 1 and Demonstration Population 2 methodology for pulling data was not correct. Eligibility staff provided corrected numbers, based upon the methodology of identifying waiver members via an ESRD enrollment file flag, for all four quarters in DY 2019. Total Enrollment in the End Stage Renal Disease Demonstration Waiver decreased considerably after the methodology was corrected.

- The total enrollment is composed of two populations. Demonstration Population 1 is defined as individuals who were “Former Spend Down Individuals/Number of Enrollees”, and Demonstration Population 2 is defined as “Number of New Enrollees”.

Continued Accessibility

Eligible ESRD enrollees covered under this demonstration waiver are Medicare beneficiaries in need of supplemental health care coverage. Continuing this coverage through the demonstration, beneficiaries are able to access fee-for-service kidney transplant and related services that they might not be able to afford by meeting the following conditions:

- Member is dually eligible for Medicare and Medicaid,
- Income is between 150% and 300% of the Federal Poverty Level (FPL),
- Resource limit is below \$1,500 per individual or \$2,250 per married couple,
- Member is not assigned to Level of Care during the month,
- Member is not in long term care during the month,
- Member is not assigned to managed care, and
- Member age is below 65 years.

Non-Emergency Medical Transportation (NEMT)

Access is also facilitated by the demonstration with the provision of Non-Emergency Medical Transportation (NEMT). Individuals affected by this demonstration shall receive benefits in the form of an administrative activity or service to assure non-emergency transportation to and from providers.

Project Status

Demonstration year 2019 was the 4th year of the ESRD Demonstration and the waiver is approved through December 31, 2020. Both P1 enrollment and P2 enrollment showed dramatic decreases for DY 2019 due to a correction in the methodology utilized for the identification of those individuals on the ESRD wavier. This document has been updated to reflect that

correction. In addition, updated DY 2016 and DY 2017 data are provided at the end of this report.

Quantitative Findings/Utilization data

Budget Neutrality

<i>Table 3 2019</i>					
ESRD Budget Neutrality Calculations					
Source: FSSA Data and Analytics					
Report the member-months for budget neutrality for each quarter of the 2019 Demonstration Year.					
Eligibility Group	Member Months Total Quarter 1 1-3/31	Member Months Total Quarter 2 4-6/30	Member Months Total Quarter 3 7-9/30	Member Months Total Quarter 4 10-12/31	Total Member Months 01/19- 12/31/19
Demonstration Population 1 – Former Spend Down Individuals	125	122	119	115	481
Demonstration Population 2 – New Enrollees	1002	994	977	955	3,928
Total	1,127	1,116	1,096	1,070	4,409
<i>Table 4 2018</i>					
ESRD Budget Neutrality Calculations					
Source: FSSA Data and Analytics					
Report the member-months for budget neutrality for each quarter of the 2018 Demonstration Year.					
Eligibility Group	Member Months Total Quarter 1 1-3/31	Member Months Total Quarter 2 4-6/30	Member Months Total Quarter 3 7-9/30	Member Months Total Quarter 4 10-12/31	Total Member Months 01/18- 12/31/18
Demonstration Population 1 – Former Spend Down Individuals	126	126	126	126	504
Demonstration Population 2 – New Enrollees	1,051	1,015	1,019	1,017	4,102
Total	1,177	1,141	1,145	1,143	4,606

Kidney Transplant List

<i>Table 5 2019</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of members on the kidney transplant list for each quarter and total for the 2019 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2019 1/19 to 12/31/19
Demonstration Population 1 – Former Spend Down Individuals	1	0	1	0	2
Demonstration Population 2 – New Enrollees	4	3	6	5	16
Total	5	3	7	5	18

<i>Table 6 2018</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of members on the kidney transplant list for each quarter and total for the 2018 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2018 1/18 to 12/31/18
Demonstration Population 1 – Former Spend Down Individuals	0	2	0	1	3
Demonstration Population 2 – New Enrollees	3	10	3	1	16
Total	3	12	3	2	19

As displayed above in Tables 5 and 6 the number of members on the kidney transplant list remained stable from 2018 to 2019. The data presented in 2018 has been updated to reflect the new methodology.

Kidney Transplant Recipients

<i>Table 7 2019</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of members who received a kidney transplant for each quarter and total for 2019 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2019 1/19 to 12/31/19
Demonstration Population 1 – Former Spend Down Individuals	11	12	13	11	14
Demonstration Population 2 – New Enrollees	41	36	46	41	68
Total	52	48	59	52	82

<i>Table 8 2018</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of members who received a kidney transplant for each quarter and total for 2018 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2018 1/18 to 12/31/18
Demonstration Population 1 – Former Spend Down Individuals	14	13	14	11	17
Demonstration Population 2 – New Enrollees	44	43	45	41	64
Total	58	56	59	52	81

Tables 7 and 8 display the number of ESRD members who received a kidney transplant. Overall, the number of members receiving kidney transplants remained stable. The number of Population 1 members who received a kidney transplant had a slight decrease compared to 2018. The data presented in 2018 has been updated to reflect the new methodology.

ESRD Mortality Figures

<i>Table 9 2019</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of members who expired due to ESRD each quarter and total for the 2019 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2019 1/19 to 12/31/19
Demonstration Population 1 – Former Spend Down Individuals	1	1	1	0	3
Demonstration Population 2 – New Enrollees	12	14	9	15	50
Total	13	15	10	15	53

<i>Table 10 2018</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of members who expired due to ESRD each quarter and total for the 2018 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2018 1/18 to 12/31/18
Demonstration Population 1 – Former Spend Down Individuals	0	0	0	0	0
Demonstration Population 2 – New Enrollees	22	15	13	5	55
Total	22	15	13	5	55

The health and survival of individuals with ESRD is dependent upon access to regular transplant and related care services. From Demonstration Year 2018 to 2019 the number of members who expired decreased by 3.6% as shown in Tables 9 and 10. The data presented in 2018 has been updated to reflect the new methodology.

Preventative and Ambulatory Services

Preventative Services

Table 11 2019

Measurement and Analysis

Source: FSSA Data and Analytics

Report the number of members 20 years and older who received a preventive care visit for each quarter and total for the 2019 Demonstration Year.

Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2019 1/19 to 12/31/19
Demonstration Population 1 – Former Spend Down Individuals	38	38	37	36	130
Demonstration Population 2 – New Enrollees	260	265	266	268	1,062
Total	298	303	303	304	1,192

Table 12 2018

Measurement and Analysis

Source: FSSA Data and Analytics

Report the number of members 20 years and older who received a preventive care visit for each quarter and total for the 2018 Demonstration Year.

Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2018 1/18 to 12/31/18
Demonstration Population 1 – Former Spend Down Individuals	37	39	38	38	152
Demonstration Population 2 – New Enrollees	267	253	256	258	1,034
Total	304	292	294	296	1,186

Ambulatory Services

<i>Table 13 2019</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of members 20 years and older who received an ambulatory care visit for each quarter and total for the 2019 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2019 1/19 to 12/31/19
Demonstration Population 1 – Former Spend Down Individuals	33	37	32	32	134
Demonstration Population 2 – New Enrollees	253	284	276	260	1,073
Total	286	321	308	292	1,207

<i>Table 14 2018</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of members 20 years and older who received an ambulatory care visit for each quarter and total for the 2018 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2018 1/18 to 12/31/18
Demonstration Population 1 – Former Spend Down Individuals	35	37	35	33	140
Demonstration Population 2 – New Enrollees	276	260	262	253	1,051
Total	311	297	297	286	1,191

Continuous monitoring of a member who has end stage renal disease and has or has yet to have a kidney transplant is an important element in slowing the progress of the disease as well as associated conditions such as high blood pressure, high blood lipids and cardiovascular disease. A comparison between Tables 11 and 12 above which show the number of waiver participants 20 years and older who received a preventive care visit from Demonstration Years 2018 to 2019. Tables 13 and 14 show the number of waiver participants who received an ambulatory care visit. The data presented in 2018 has been updated to reflect the new methodology.

Flu Vaccination Enrollees

<i>Table 15 2019</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of older adult members 45 to 64 years who received a flu vaccination for each quarter and total for the 2019 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for 2019 Ending 12/31/19
Demonstration Population 1 – Former Spend Down Individuals	13	13	0	0	13
Demonstration Population 2 – New Enrollees	54	52	51	50	54
Total	67	65	63	62	67

<i>Table 16 2018</i>					
Measurement and Analysis					
Source: FSSA Data and Analytics					
Report the number of older adult members 45 to 64 years who received a flu vaccination for each quarter and total for the 2018 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for 2018 Ending 12/31/18
Demonstration Population 1 – Former Spend Down Individuals	13	13	13	13	13
Demonstration Population 2 – New Enrollees	59	54	54	54	59
Total	72	67	67	67	72

“Vaccination of Dialysis Patients and Patients with Chronic Kidney Disease (CKD)” is important “because incidence or severity of some vaccine-preventable diseases is higher in persons who are immunocompromised; therefore, certain vaccines (e.g., inactivated influenza vaccine and pneumococcal vaccines) are recommended specifically for persons with immune compromise.” Tables 15 and 16 above show older adult members 45 to 64 years who received a flu vaccination from DY 2018 to DY 2019. There was a slight decrease in flu vaccinations in 2019 compared to 2018.

(https://www.cdc.gov/dialysis/PDFs/Vaccinating_Dialysis_Patients_and_Patients_dec2012.pdf).

2019 Annual Evaluation Findings

The Indiana End Stage Renal Disease (ESRD) program began in May 2014 as a part of the Healthy Indiana Plan (HIP) 1.0. The demonstration was renewed and renamed in 2016 as the End Stage Renal Disease (ESRD) Demonstration and approved through December 31, 2020. At inception the demonstration covered approximately 1,216 individuals with ESRD (P1 & P2). During the first quarter of FFY1019 staff from the Quality and Outcomes Section of the Indiana Office of Medicaid Policy and Planning (OMPP) became involved in the project to revise the 2018 CMS-

64 to include data on the end stage renal disease population and budget neutrality for this waiver. In meetings with Enrollment staff it was discovered that the Demonstration Population 1 and Demonstration Population 2 methodology for pulling data was not correct. Eligibility staff provided corrected numbers, based upon the methodology of identifying participants by an ESRD enrollment file flag, for all four quarters in DY 2019. Total Enrollment in the End Stage Renal Disease Demonstration Waiver decreased considerably after the methodology was corrected.

The objectives of the demonstration are:

- Increase overall coverage of low-income individuals with a diagnosis of ESRD in the state; and
- Ensure access to comprehensive coverage for low-income individuals who have a diagnosis of ESRD and primary coverage through Medicare.

With the 2019 revision in methodology for gathering data on Indiana's ESRD waiver participants, no comparison can be made between Demonstration Years 2018 and 2019. The ESRD waiver has in the past and continues to provide essential medical coverage to its participants as they experience the effects of kidney disease.

Updated DY 2016 and DY 2017 data are presented here. These data reflect the updated methodology discussed in *Project Status*.

<i>Table 1 2016</i>				
ESRD-Enrollment				
Source: Family & Social Services Administration (FSSA) Data and Analytics				
Report the unduplicated count of members enrolled as of the last day of the reporting quarters.				
	Total by Quarter			
Population	3/16	6/16	9/16	12/16
Demonstration Population 1 – Former Spend Down Individuals/Number of Enrollees	39	39	40	41
Demonstration Population 2 - Number of New Enrollees	371	364	368	368
Demonstration Population Total Number of Enrollees	410	403	408	409

<i>Table 2 2017</i>				
ESRD-Enrollment				
Source: Family & Social Services Administration (FSSA) Data and Analytics				
Report the unduplicated count of members enrolled as of the last day of the reporting quarters.				
	Total by Quarter			
Population	3/17	6/17	9/17	12/17
Demonstration Population 1 – Former Spend Down Individuals/Number of Enrollees	42	42	42	42
Demonstration Population 2 - Number of New Enrollees	372	371	364	362
Demonstration Population Total Number of Enrollees	414	413	406	404

<i>Table 3 2016</i>					
Kidney Transplant List					
Source: FSSA Data and Analytics					
Report the number of members on the kidney transplant list for each quarter and total for the 2016 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2016 1/16 to 12/31/16
Demonstration Population 1 – Former Spend Down Individuals	0	1	1	0	2
Demonstration Population 2 – New Enrollees	2	2	8	5	17
Total	2	3	9	5	19

<i>Table 4 2017</i>					
Kidney Transplant List					
Source: FSSA Data and Analytics					
Report the number of members on the kidney transplant list for each quarter and total for the 2017 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2017 1/17 to 12/31/17
Demonstration Population 1 – Former Spend Down Individuals	0	1	0	0	1
Demonstration Population 2 – New Enrollees	3	1	4	3	11
Total	3	2	4	3	12

Updated DY 2016 and DY 2017 data are presented here. These data reflect the updated methodology discussed in *Project Status*.

<i>Table 5 2016</i>					
Kidney Transplant Recipients					
Source: FSSA Data and Analytics					
Report the number of members who received a kidney transplant for each quarter and total for 2016 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2016 1/16 to 12/31/16
Demonstration Population 1 – Former Spend Down Individuals	4	5	5	8	9
Demonstration Population 2 – New Enrollees	33	27	28	34	48
Total	37	32	33	42	57

<i>Table 6 2017</i>					
Kidney Recipient List					
Source: FSSA Data and Analytics					
Report the number of members who received a kidney transplant for each quarter and total for 2017 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2017 1/17 to 12/31/17
Demonstration Population 1 – Former Spend Down Individuals	7	10	8	11	14
Demonstration Population 2 – New Enrollees	40	40	33	34	56
Total	47	50	41	45	70

Updated DY 2016 and DY 2017 data are presented here. These data reflect the updated methodology discussed in *Project Status*.

<i>Table 7 2016</i>					
ESRD Mortality Figures					
Source: FSSA Data and Analytics					
Report the number of members who expired due to ESRD each quarter and total for the 2016 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2016 1/16 to 12/31/16
Demonstration Population 1 – Former Spend Down Individuals	0	0	0	0	0
Demonstration Population 2 – New Enrollees	13	8	8	12	41
Total	13	8	8	12	41

<i>Table 8 2017</i>					
ESRD Mortality Figures					
Source: FSSA Data and Analytics					
Report the number of members who expired due to ESRD each quarter and total for the 2017 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	Total Members for DY 2017 1/17 to 12/31/17
Demonstration Population 1 – Former Spend Down Individuals	0	0	0	0	0
Demonstration Population 2 – New Enrollees	8	14	12	7	41
Total	8	14	12	7	41

Updated DY 2016 and DY 2017 data are presented here. These data reflect the updated methodology discussed in *Project Status*.

<i>Table 9 2016</i>					
Preventive Care Visits					
Source: FSSA Data and Analytics					
Report the number of members 20 years and older who received a preventive care visit for each quarter and total for the 2016 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	
Demonstration Population 1 – Former Spend Down Individuals	29	32	33	33	
Demonstration Population 2 – New Enrollees	260	264	256	267	
Total	289	296	289	300	

<i>Table 10 2017</i>					
Preventive Care Visits					
Source: FSSA Data and Analytics					
Report the number of members 20 years and older who received a preventive care visit for each quarter and total for the 2017 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	
Demonstration Population 1 – Former Spend Down Individuals	34	35	36	37	
Demonstration Population 2 – New Enrollees	261	261	264	262	
Total	295	296	300	299	

Updated DY 2016 and DY 2017 data are presented here. These data reflect the updated methodology discussed in *Project Status*.

<i>Table 11 2016</i>					
Ambulatory Care Visits					
Source: FSSA Data and Analytics					
Report the number of members 20 years and older who received an ambulatory care visit for each quarter and total for the 2016 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	
Demonstration Population 1 – Former Spend Down Individuals	27	27	25	30	
Demonstration Population 2 – New Enrollees	264	270	253	258	
Total	291	297	278	288	

<i>Table 12 2017</i>					
Preventive Care Visits					
Source: FSSA Data and Analytics					
Report the number of members 20 years and older who received an ambulatory care visit for each quarter and total for the 2017 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	
Demonstration Population 1 – Former Spend Down Individuals	34	33	33	34	
Demonstration Population 2 – New Enrollees	268	268	256	246	
Total	302	301	289	280	

Updated DY 2016 and DY 2017 data are presented here. These data reflect the updated methodology discussed in *Project Status*.

<i>Table 13 2016</i>					
Flu vaccinations					
Source: FSSA Data and Analytics					
Report the number of older adult members 45 to 64 years who received a flu vaccination for each quarter and total for the 2016 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	
Demonstration Population 1 – Former Spend Down Individuals	13	13	13	13	
Demonstration Population 2 – New Enrollees	54	54	57	57	
Total	67	67	70	70	
Flu vaccinations					
Source: FSSA Data and Analytics					
Report the number of older adult members 45 to 64 years who received a flu vaccination for each quarter and total for the 2017 Demonstration Year.					
Eligibility Group	Number of Members Quarter 1	Number of Members Quarter 2	Number of Members Quarter 3	Number of Members Quarter 4	
Demonstration Population 1 – Former Spend Down Individuals	13	13	13	13	
Demonstration Population 2 – New Enrollees	57	61	64	63	
Total	70	74	77	76	